Pazopanib, a multi-kinase angiogenesis inhibitor targeting c-Kit, VEGFR-1 and VEGFR-2, PDGFR-α and -β, was the first tyrosine kinase inhibitor approved by the FDA for the treatment of refractory soft tissue sarcomas in 2012, based on results of the phase III randomized double-blinded placebo-controlled PALETTE trial that demonstrated improved progression-free survival but not overall survival in adults with advanced non-adipocytic soft tissue sarcoma [180]. Here, PDGFRA is linked to soft tissue sarcoma.